Patents Assigned to Array Biopharma Inc.
  • Patent number: 7598383
    Abstract: Disclosed are compounds of the Formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R7, R8 and R9, W, X and Y are as defined in the specifications. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: November 18, 2004
    Date of Patent: October 6, 2009
    Assignee: Array Biopharma Inc.
    Inventors: Allison L. Marlow, Eli Wallace, Jeongbeob Seo, Joseph P. Lyssikatos, Hong Woon Yang, James Blake
  • Publication number: 20090247526
    Abstract: Provided are compounds of formula I wherein R2, L, Z, Y, G and R1 are as defined herein, that are useful in the treatment and/or prevention of diseases or disorders mediated by deficient levels of glucokinase activity or which can be treated by activating glucokinase including, but not limited to, diabetes mellitus, impaired glucose tolerance, IFG (impaired fasting glucose) and IFG (impaired fasting glycemia), as well as other diseases and disorders such as those discussed herein.
    Type: Application
    Filed: January 24, 2007
    Publication date: October 1, 2009
    Applicant: ARRAY BIOPHARMA INC.
    Inventors: Thomas D. Aicher, Steven Armen Boyd, Mark Joseph Chicarelli, Kevin Ronald Condroski, Rustam Ferdinand Garrey, Ronald Jay Hinklin, Ajay Singh, Timothy M. Turner
  • Publication number: 20090246274
    Abstract: The invention concerns pharmaceutical compositions containing a hydrogen sulphate salt of 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide and solvates, crystalline forms and amorphous forms thereof, to the use of said compositions as a medicament; and to processes for the preparation of said compositions.
    Type: Application
    Filed: March 26, 2009
    Publication date: October 1, 2009
    Applicants: AstraZeneca AB, Array Biopharma, Inc.
    Inventors: Nicola Frances Bateman, Paul Richard Gellert, Kathryn Jane Hill
  • Patent number: 7585975
    Abstract: This invention concerns quinazoline analogs of Formula I: where an A group is bonded to at least one of the carbons at the 5, 6, 7 or 8 position of the bicyclic ring, and the ring is substituted by up to three independent R3 groups. The invention also includes methods of using these compounds as type I receptor tyrosine kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
    Type: Grant
    Filed: April 21, 2008
    Date of Patent: September 8, 2009
    Assignee: Array BioPharma Inc.
    Inventors: Eli Wallace, George Topalov, Joseph Lyssikatos, Alexandre Buckmelter, Qian Zhao
  • Publication number: 20090215834
    Abstract: Disclosed are compounds of the Formula V and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R7, R8 and R9, and W are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, and inflammatory conditions in mammals. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases and inflammatory conditions in mammals and pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: August 5, 2008
    Publication date: August 27, 2009
    Applicant: Array BioPharma Inc.
    Inventors: Allison L. Marlow, Eli Wallace, Jeongbeob Seo, Joseph P. Lyssikatos, Hong Woon Yang, James Blake
  • Publication number: 20090209554
    Abstract: The present invention provides N-3?-pyridyl-methyl or N-2?-pyrazinylmethyl thiazolium derivatives of formula (I) which are useful as transketolase inhibitors wherein R1, R2, R3, Y, R5-R9, Ra-Rd, n and X? are as defined herein. The present invention also provides pharmaceutical compositions comprising the compounds of formula (I). The invention provides methods for inhibiting transketolase activity, reducing cellular ribose-5-phosphate levels, inhibiting nucleic acid synthesis, inhibiting cell proliferation and tumor cell growth in vitro and in vivo, stimulating apoptosis in tumor cells and treating cancer by administering a compound of formula (I) or a pharmaceutical composition thereof.
    Type: Application
    Filed: March 23, 2005
    Publication date: August 20, 2009
    Applicant: ARRAY BIOPHARMA INC.
    Inventors: Steven A. Boyd, Kevin R. Condroski, Jason De Meese, Stephen S. Gonzales, Indrani W. Gunawardana, Tomas Kaplan, Yvan Le Huerou, Joseph Lyssikatos, Todd T. Romoff, Francis X. Sullivan, Allen Thomas
  • Publication number: 20090209542
    Abstract: Disclosed are compounds of the Formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R7, R8, R9, and W are as defined in the specification. Such compounds are MEK inhibitors and are useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, and inflammatory conditions in mammals. Also disclosed are methods of using such compounds in the treatment of hyperproliferative and inflammatory diseases in mammals and pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: August 5, 2008
    Publication date: August 20, 2009
    Applicant: Array BioPharma Inc.
    Inventors: Allison L. Marlow, Eli Wallance, Jeongbeob Seo, Joseph P. Lyssikatos, Hong Woon Yang, James Blake
  • Patent number: 7576114
    Abstract: Disclosed are compounds of the Formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein W, R1, R2, R7, R8, R9 and R10 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals. Also disclosed is a method of using such compounds in the treatment of hyperproliferative diseases in mammals, and pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: March 18, 2008
    Date of Patent: August 18, 2009
    Assignee: Array BioPharma Inc.
    Inventors: Eli M. Wallace, Joseph P. Lyssikatos, Allison L. Marlow, T. Brian Hurley
  • Patent number: 7576072
    Abstract: Disclosed are compounds of the Formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R7, R8 and R9, W, X, Y and Z are as defined in the specification. Such compounds are MEK inhibitors and are useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: November 18, 2004
    Date of Patent: August 18, 2009
    Assignee: Array BioPharma Inc.
    Inventors: Eli Wallace, Jeongbeob Seo, Joseph P. Lyssikatos, Hong Woon Yang, T. Brian Hurley, Allison L. Marlow, James Blake
  • Patent number: 7566716
    Abstract: Compounds of Formula I are useful for inhibiting Raf kinase and for treating disorders mediated thereby. Methods of using compounds of Formula I, and stereoisomers, tautomers, solvates and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
    Type: Grant
    Filed: May 18, 2006
    Date of Patent: July 28, 2009
    Assignee: Array Biopharma Inc.
    Inventors: Ellen Laird, George Topalov, Joseph P. Lyssikatos, Mike Welch, Jonas Grina, Josh Hansen, Brad Newhouse
  • Publication number: 20090169510
    Abstract: The embodiments provide compounds of the general Formulae I through general Formula VIII, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.
    Type: Application
    Filed: April 18, 2008
    Publication date: July 2, 2009
    Applicants: InterMune, Inc., Array BioPharma, Inc.
    Inventors: Lawrence M Blatt, Scott D. Seiwert, Steven W. Andrews, Pierre Martin, Andreas Schumacher, Bradley Barnett, C. Todd Eary, Robert Kaus, Timothy Kercher, Weidong Liu, Michael Lyon, Paul Nichols, Bin Wang, Tarek Sammakia, April Kennedy, Yutong Jiang
  • Patent number: 7553842
    Abstract: Disclosed are compounds of the Formula I and diastereomers, tautomers, solvates, metabolites, and pharmaceutically acceptable salts thereof, wherein X, A, L and Y are as defined herein. Such compounds are useful in the treatment of immunoregulatory and respiratory diseases in mammals. Also disclosed are methods of using such compounds in the treatment of immunoregulatory and respiratory diseases in mammals and pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: January 19, 2006
    Date of Patent: June 30, 2009
    Assignee: Array Biopharma Inc.
    Inventors: Stephen T. Schlacter, John J. Gaudino, Laurence E. Burgess, Kevin W. Hunt
  • Publication number: 20090156603
    Abstract: Provided are compounds of formula I that are useful in the treatment and/or prevention of diseases mediated by deficient levels of glucokinase activity, such as diabetes meilitus. Also provided are methods of treating or preventing diseases and disorders characterized by underactivity of glucokinase or which can be treated by activating glucokinase.
    Type: Application
    Filed: March 23, 2007
    Publication date: June 18, 2009
    Applicant: Array BioPharma Inc.
    Inventors: Thomas D. Aicher, Steven Armen Boyd, Mark Joseph Chicarelli, Kevin Ronald Condroski, Ronald Jay Hinklin, Ajay Singh
  • Publication number: 20090148407
    Abstract: The embodiments provide compounds of the general Formulae (I) through general Formula (VIII), as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.
    Type: Application
    Filed: July 17, 2006
    Publication date: June 11, 2009
    Applicants: Intermune, Inc., Array Biopharma Inc.
    Inventors: Lawrence M. Blatt, Scott D. Seiwert, Steven W. Andrews, Pierre Martin, Andreas Schumacher, Bradley Barnett, C. Todd Eary, Robert Kaus, Timothy Kercher, Weidong Liu, Michael Lyon, Paul Nichols, Bin Wang, Tarek Sammakia, April Kennedy, Yutong Jiang
  • Publication number: 20090149459
    Abstract: This invention relates to inhibitors of p38 and methods of utilizing the inhibitors and pharmaceutical compositions thereof in the treatment and prevention of various disorders mediated by p38.
    Type: Application
    Filed: February 2, 2009
    Publication date: June 11, 2009
    Applicant: ARRAY BIOPHARMA INC.
    Inventors: Mark Munson, David A. Mareska, Youngboo Kim, Robert D. Groneberg, James Rizzi, Martha Rodriguez, Ganghyeok Kim, Guy Vigers, Chang Rao, Devan Balachari, Darren Harvey
  • Publication number: 20090143389
    Abstract: Disclosed are compounds of the Formulas III and IV and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R7, R8, R9, and R10 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: January 20, 2009
    Publication date: June 4, 2009
    Applicant: ARRAY BIOPHARMA INC.
    Inventors: James F. Blake, Joseph P. Lyssikatos, Hong-Woon Yang, Eli M. Wallace
  • Publication number: 20090143579
    Abstract: Disclosed are compounds of the Formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R7, R8, R9, W, X and Y are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: January 20, 2009
    Publication date: June 4, 2009
    Applicant: ARRAY BIOPHARMA INC.
    Inventors: James F. Blake, Joseph P. Lyssikatos, Hong-Woon Yang, Eli M. Wallace, Jeongbeob Seo
  • Publication number: 20090143422
    Abstract: This invention relates to inhibitors of p38 and methods of utilizing the inhibitors and pharmaceutical compositions thereof in the treatment and prevention of various disorders mediated by p38.
    Type: Application
    Filed: February 2, 2009
    Publication date: June 4, 2009
    Applicant: ARRAY BIOPHARMA INC.
    Inventors: Mark Munson, David A. Mareska, Youngboo Kim, Robert D. Groneberg, James Rizzi, Martha Rodriguez, Ganghyeok Kim, Guy Vigers, Chang Rao, Devan Balachari, Darren Harvey
  • Publication number: 20090136596
    Abstract: This invention relates to inhibitors of p38 and methods of utilizing the inhibitors and pharmaceutical compositions thereof in the treatment and prevention of various disorders mediated by p38.
    Type: Application
    Filed: February 2, 2009
    Publication date: May 28, 2009
    Applicant: Array BioPharma Inc.
    Inventors: Mark Munson, David A. Mareska, Youngboo Kim, Robert D. Groneberg, James Rizzi, Martha Rodriguez, Ganghyeok Kim, Guy Vigers, Chang Rao, Devan Balachari, Darren Harvey
  • Patent number: 7538120
    Abstract: Disclosed are methods of treating inflammatory diseases and disorders, such as arthritis and inflammatory bowel disease, in mammals.
    Type: Grant
    Filed: August 19, 2005
    Date of Patent: May 26, 2009
    Assignee: Array Biopharma Inc.
    Inventors: Kevin Koch, T. Brian Hurley, Hong Woon Yang, Joseph Lyssikatos, James F. Blake, Allison L. Marlow, Eli M. Wallace